In 2025, Isofol took several steps in the development of the drug candidate arfolitixorin, a drug candidate that can improve the effect of standard treatment for disseminated colorectal cancer and other cancers. The year was marked by scientific advances, building medical and scientific expertise, regulatory progress in Europe and the US, the start of a new clinical study and a deepened relationship with the Japanese partner Solasia Pharma KK. 2026 is expected to be at least as eventful with several value-adding activities on the horizon.

Read the interview at biostock.se:
https://biostock.se/en/2026/01/tillbaka-pa-banan-2025-var-ett-ar-av-kliniska-framsteg-for-isofol-som-aterstartat-studier-med-arfolitixorin/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!  

About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital. 

Läs mer på BioStock